Talk:Bromazolam: Difference between revisions
>OddPlague Added description, history, pharmacology |
>Tracer m Tracer moved page Bromazolam to Talk:Bromazolam: Moved to talk page |
||
(90 intermediate revisions by 19 users not shown) | |||
Line 1: | Line 1: | ||
{{decree|type=notice|message=This article is currently in the 'Talk' namespace as an unfinished draft. This section is used to host drafts for unpublished articles and discussions of published ones. If you wish to discuss or suggest improvements to this draft, please do so in the 'Discussion' section at the bottom of the page. This notice will be removed once the draft has been approved for publication by an administrator.}}{{headerpanel|{{Approval}}}} | |||
<br /> | |||
{{ | {{headerpanel|{{DepressantOD|benzodiazepines}}}} | ||
{{Distinguish|Flubromazolam}} | |||
{{SummarySheet}} | |||
{{SubstanceBox/Bromazolam}} | |||
''Bromazolam''' (also known as '''Brom''', '''Bromaz''', or '''XLI-268''') is a [[psychoactive class::depressant]] | '''Bromazolam''' (also known as '''Brom''', '''Bromaz''', or '''XLI-268''') is a novel [[psychoactive class::depressant]] belonging to the [[chemical class::benzodiazepine]] class. It exhibits [[anxiolytic]], [[disinhibition]], [[sedative]], [[muscle relaxant]], and [[memory suppression]] effects when administered. Bromazolam is not currently scheduled in many regions globally and is frequently distributed online as a [[research chemical]]. Structurally, it is the bromine-substituted analogue of [[alprazolam]] and has similar pharmacokinetic properties and subjective effects. | ||
Like other [[benzodiazepines]], | Like other [[benzodiazepines]], Bromazolam binds to specific sites on the [[GABA<sub>A</sub> receptor]] in the brain, amplifying the inhibitory effects of gamma-aminobutyric acid (GABA).<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303399/</ref> Its availability on the [[clearnet]] and [[darknet]] has increased its use for self-medication and recreational purposes due to its potent effects. | ||
It is important to note that the pharmacological properties stated are assumed based on its structure and user reports, as no extensive formal research has been conducted. | |||
< | The [[benzodiazepine#Discontinuation|sudden discontinuation of benzodiazepines]] after prolonged use can lead to severe withdrawal symptoms, including seizures or death.<ref>A fatal case of benzodiazepine withdrawal. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/19465812</ref> Users are strongly advised to [[taper]] their dosage gradually rather than stopping abruptly.<ref>Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain - Appendix B-6: Benzodiazepine Tapering | http://nationalpaincentre.mcmaster.ca/opioid/cgop_b_app_b06.html</ref> | ||
==History and Culture== | |||
[[Bromazolam]] (XLI-268) is a [[triazolobenzodiazepine]] (TBZD) first synthesized in 1976 by Hoffman-La Roche. Although initially developed as a potential medication, it was never approved for use and remained unmarketed.<ref>Manchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD (January 2018). "The emergence of new psychoactive substance (NPS) benzodiazepines: A review". Drug Testing and Analysis. 10 (1): 37–53. doi:10.1002/dta.2211. <nowiki>PMID 28471096</nowiki>. </ref> Bromazolam was first identified in Sweden in 2016 by the EMCDDA and has since been found in nine countries, including Australia, Austria, China, Finland, Germany, India, Sweden, the UK, and the USA. | |||
In European markets, Bromazolam is often sold as blue Diazepam pills,<ref>https://www.wedinos.org/sample-results</ref> while in the United States, it is more commonly sold as Alprazolam. | |||
Bromazolam | |||
==Chemistry== | ==Chemistry== | ||
[[File:Alprazolam vs bromazolam.jpg|alt=Comparison between the molecular structures of alprazolam and bromazolam|thumb|323x323px|Chemical structural comparison of Alprazolam and Bromazolam by Kevin G. Shanks (2023).]] | |||
Bromazolam is a chemical analog of [[alprazolam]], where the chlorine atom in alprazolam is replaced by a bromine atom. | |||
==Pharmacology== | ==Pharmacology== | ||
Bromazolam is a triazolobenzodiazepine (TBZD) and was synthesized in 1976, though it was not brought to market.<ref>Manchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD (January 2018). "The emergence of new psychoactive substance (NPS) benzodiazepines: A review". Drug Testing and Analysis. 10 (1): 37–53. doi:10.1002/dta.2211. <nowiki>PMID 28471096</nowiki>. </ref> It acts as a non-subtype selective agonist at the benzodiazepine (BZD) site of [[GABA<sub>A</sub> receptors]], with a binding affinity of 2.81nM at the α1 subtype, 0.69nM at α2, and 0.62nM at α5.<ref>Benzodiazepine interactions with GABA receptors (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/6147796</ref> Benzodiazepines enhance the efficiency of GABA neurotransmission, producing sedating and anxiolytic effects<ref>http://www.ncbi.nlm.nih.gov/pubmed/2450203</ref>. | |||
Bromazolam is a triazolobenzodiazepine (TBZD) | |||
The GABA<sub>A</sub> receptor consists of five subunits out of a possible 19, leading to a wide variety of receptor subtypes with different properties and interactions with benzodiazepines. Triazolobenzodiazepines like Bromazolam may also possess antidepressant properties, potentially due to their chemical similarity to tricyclic antidepressants.<ref>Barbee JG (October 1993). "Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives". ''The Journal of Clinical Psychiatry''. 54 Suppl (Suppl): 86–97, discussion 98–101. <nowiki>PMID 8262893</nowiki>.</ref> | |||
==Half Life== | |||
4-8 hours with after effects being reported into the next 12 hours. In some cases people have reported feeling anxiolytic effects well into the 24+ hour mark and withdrawals/rebound anxiety not starting until Day 4/5. | |||
==Subjective | ==Subjective Effects== | ||
{{EffectStub}}Bromazolam's | {{EffectStub}} | ||
Bromazolam's subjective effects include sedation, relaxation, anxiety suppression, and decreased inhibition. | |||
{{Preamble/SubjectiveEffects}} | |||
{{effects/base | {{effects/base | ||
|{{effects/physical| | |{{effects/physical| | ||
Bromazolam | Physical effects of Bromazolam are generally marked by intense sedation, sleepiness, and muscle relaxation. | ||
*'''[[Effect::Sedation]]''' | * '''[[Effect::Sedation]]''' – Can lead to profound drowsiness, including sudden onset of extreme fatigue and "nodding off." | ||
*'''[[Effect::Perception of bodily heaviness]]''' | * '''[[Effect::Perception of bodily heaviness]]''' – Often accompanies moderate to high doses, leading to a lethargic state where movement is difficult. | ||
*'''[[Effect::Appetite enhancement]]''' | * '''[[Effect::Appetite enhancement]]''' – Reported to stimulate hunger in a manner akin to alcohol. | ||
*'''[[Effect::Muscle relaxation]]''' | * '''[[Effect::Muscle relaxation]]''' – Effects are more pronounced than with [[alcohol]]. | ||
*'''[[Effect::Motor control loss]]''' | * '''[[Effect::Motor control loss]]''' – Causes stumbling, clumsiness, and escalated injury risks at higher doses. | ||
*'''[[Effect::Respiratory depression]]''' | * '''[[Effect::Respiratory depression]]''' – Potent at higher doses, it can be fatal when combined with other depressants. | ||
*'''[[Effect::Dizziness]]''' | * '''[[Effect::Dizziness]]''' – Common, especially at high doses. | ||
*'''[[Effect::Seizure suppression]]''' | * '''[[Effect::Seizure suppression]]''' – May provide anti-convulsant effects like other benzodiazepines. | ||
}} | }} | ||
{{effects/visual| | {{effects/visual| | ||
Bromazolam | Bromazolam can suppress visual acuity, resulting in blurred vision, especially at higher doses. | ||
* '''[[Effect::Visual acuity suppression]]''' | |||
*'''[[Effect:: | * '''[[Effect::Blurred vision]]''' | ||
*'''[[Effect:: | * '''[[Effect::Double vision]] | ||
}} | }} | ||
|{{effects/cognitive| | |{{effects/cognitive| | ||
Bromazolam | Bromazolam primarily impacts cognitive functions such as memory, emotion, and judgment. | ||
*'''[[Effect::Analysis suppression]]''' | * '''[[Effect::Analysis suppression]]''' | ||
*'''[[Effect::Anxiety suppression]]''' | * '''[[Effect::Anxiety suppression]]''' | ||
*'''[[Effect::Compulsive redosing]]''' | * '''[[Effect::Compulsive redosing]]''' – Disinhibition combined with memory suppression may lead to frequent and uncontrolled redosing, increasing overdose risk. | ||
*'''[[Effect::Confusion]]''' | * '''[[Effect::Confusion]]''' | ||
*'''[[Effect::Delusions|Delusions of sobriety]]''' | * '''[[Effect::Delusions|Delusions of sobriety]]''' | ||
*'''[[Effect::Disinhibition]] | * '''[[Effect::Disinhibition]]''' | ||
*'''[[Effect::Dream suppression]]''' | * '''[[Effect::Dream suppression]]''' | ||
*'''[[Effect::Emotion suppression]]''' | * '''[[Effect::Emotion suppression]]''' | ||
*'''[[Effect::Euphoria]]''' | * '''[[Effect::Euphoria]]''' | ||
*'''[[Effect::Language suppression]]''' | * '''[[Effect::Language suppression]]''' | ||
*'''[[Effect::Memory suppression]]''' | * '''[[Effect::Memory suppression]]''' | ||
**'''[[Effect::Amnesia]]''' | * ** '''[[Effect::Amnesia]]''' – Particularly at high doses, Bromazolam can cause blackouts, making users forget periods while under its influence. | ||
*'''[[Effect::Motivation suppression]]''' | * '''[[Effect::Motivation suppression]]''' | ||
*'''[[Effect::Sleepiness]]''' | * '''[[Effect::Sleepiness]]''' | ||
*'''[[Effect::Thought deceleration]]''' | * '''[[Effect::Thought deceleration]]''' | ||
}} | }} | ||
{{effects/aftereffects| | {{effects/aftereffects| | ||
* '''Rebound [[Effect::Anxiety]]''' | |||
* '''[[Effect::Dream potentiation]]''' <ref>Goyal, Sarita. "Drugs and Dreams." Indian Journal of Clinical Practice (n.d.): n. pag. Web. | http://medind.nic.in/iaa/t13/i3/iaat13i3p624.pdf</ref> | |||
* '''Residual [[Effect::Sleepiness]]''' | |||
* '''[[Effect::Thought deceleration]]''' | |||
* '''[[Effect::Thought disorganization]]''' | |||
* '''[[Effect::Irritability]]''' | |||
}}}} | |||
===Experience Reports=== | |||
There are currently {{#ask:[[Category:Bromazolam]][[Category:Experience]] | format=count}} experience reports available in our [[experience index]]. | |||
Additional experience reports for Bromazolam can be found here: | |||
*[https://www.erowid.org/experiences/subs/exp_Bromazolam_Retrospective_I_Summary.shtml Erowid Experience Vaults: Bromazolam] | |||
== | |||
==Toxicity and Harm Potential== | |||
{{toxicity|Dosage=0.5-1 mg - Light<br> 1 mg-3 mg - Moderate<br> 3 mg-5 mg+ - Strong}} | |||
Research on the toxicity of Bromazolam has not been done, however there large amounts of overdoses have been reported in relation to Bromazolam. It is strongly recommended to employ [[responsible use|harm reduction practices]] while using this or any substance. | |||
===Tolerance and Addiction Potential=== | |||
Long-term use of Bromazolam can lead to tolerance, physical dependence, and withdrawal symptoms associated with benzodiazepines, including the potential for life-threatening withdrawal seizures. Notably, tolerance to Bromazolam builds more quickly than with other benzodiazepines, increasing the risk of dependence. | |||
===Dangerous Interactions=== | |||
Like other benzodiazepines, Bromazolam should not be mixed with alcohol or other central nervous system depressants due to the high risk of fatal overdose caused by respiratory depression. | |||
{{DangerousInteractions}} | {{DangerousInteractions}} | ||
{{DangerousInteractions/Intro}} | {{DangerousInteractions/Intro}} | ||
==Legal | {{DangerousInteractions/Depressants}} | ||
==Legal Status== | |||
[[Bromazolam]] is currently unscheduled in many countries, though some states and nations have specific controls: | |||
- **United Kingdom:** Classified as a Class C controlled substance.<ref>https://publichealthscotland.scot/publications/rapid-action-drug-alerts-and-response-radar-alerts/radar-bromazolam-alert-2023/legal-status/#:~:text=In%20the%20UK%2C%20many%20benzodiazepines,be%20due%20to%20international%20control.</ref> | |||
- **United States:** Federally unscheduled, though state-level regulations like in Virginia have placed Bromazolam into Schedule I.<ref>https://web.archive.org/web/20230323012949/https://law.lis.virginia.gov/vacode/title54.1/chapter34/section54.1-3446/</ref>. | |||
- **Canada:** Classified as a Schedule IV controlled substance. | |||
- **Germany:** Subject to national control legislation. | |||
==See | ==See Also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
==External | ==External Links== | ||
*[https://en.wikipedia.org/wiki/ | *[https://en.wikipedia.org/wiki/Bromazolam Bromazolam (Wikipedia)] | ||
* | *[https://www.erowid.org/experiences/subs/exp_Bromazolam.shtml Bromazolam (Erowid Vault)] | ||
* | *[https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=3065 Bromazolam (Isomer Design)] | ||
*[https://cdn.who.int/media/docs/default-source/46th-ecdd/bromazolam_46th-ecdd-critical-review_public-version.pdf?sfvrsn=4f1bccfa_1 WHO Critical Report October 2023] | |||
==Literature== | ==Literature== | ||
*APA formatted | *APA formatted references | ||
Refer to the [[citation formatting guide]] for help in properly formatting citations. | |||
==References== | ==References== |